Convulsion due to Ertapenem in a Renal Transplant Patient

We present a 53-year-old kidney transplantrecipient with generalized convulsions who had renal dysfunction and was under ertapenem treatment due to urinary tractinfection.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:A new generation carbapenem, ertapenem has an important advantage as it can be administered once a day.

📊

Key Findings & Data:Among carbapenems imipenem is known to have neurotoxic side effects and reduces the seizure threshold in the kidney diseases’patient population.

💡

Conclusion & Impact:We present a 53-year-old kidney transplantrecipient with generalized convulsions who had renal dysfunction and was under ertapenem treatment due to urinary tractinfection.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

A new generation carbapenem, ertapenem has an important advantage as it can be administered once a day. Among carbapenems imipenem is known to have neurotoxic side effects and reduces the seizure threshold in the kidney diseases’patient population. Rare cases of ertapenem neurotoxicity have been reported. We present a 53-year-old kidney transplantrecipient with generalized convulsions who had renal dysfunction and was under ertapenem treatment due to urinary tractinfection.

🔖

Cite This Article

ŞENEL, E., GÜZEL, F. B., AĞAOĞLU, A. B., NAZİK, S., ERKEN, E., ALTUNÖREN, O., GÜNGÖR, Ö. (2019). Convulsion due to Ertapenem in a Renal Transplant Patient. Turkish journal of nephrology (Online), Cilt: 28 - Sayı: 2, 150–153. https://ajindex.com/articles/374917

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-42. [CrossRef] 2. Oo Y, Packham D, Yau W, Munckhof WJ. Ertapenem-associated psychosis and encephalopathy. Intern Med J 2014; 44: 817-9. [CrossRef] 3. Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of Ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. J Clin Pharm Ther 2015; 40: 240-4. [CrossRef] 4. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of Ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 Suppl 2: ii23-8. [CrossRef] 5. Lee YC, Huang YJ, Hung MC, Hung SC, Hsiao CY, Cho HL, et al. Risk factors associated with the development of seizures among adult patients treated with Ertapenem: A matched case-control study. PLoS One 2017; 12: e0182046. [CrossRef] 6. Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function J Investig Med High Impact Case Rep 2017; 5: 2324709616689376. 7. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011; 31: 408-23. [CrossRef] 8. Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69: 2043-55. [CrossRef] 9. Nierenberg DW. Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings. J Pharmacol Exp Ther 1987; 240: 712-6. 10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45. [CrossRef] 11. Lin H, Chew STH. Status Epilepticus and Delirium Associated with Ertapenem in a Very Elderly Patient with Chronic Kidney Disease and Silent Ischaemic Cerebrovascular Disease. Drug Saf Case Rep 2015; 2: 19. [CrossRef] 12. Wen MJ, Sung CC, Chau T, Lin SH. Acute prolonged neurotoxicity associated with recommended doses of Ertapenem in 2 patients with advanced renal failure. Clin Nephrol 2013; 80: 474-8. [CrossRef]